169 related articles for article (PubMed ID: 32594568)
1. TP53 R249S mutation detected in circulating tumour DNA is associated with Prognosis of hepatocellular carcinoma patients with or without hepatectomy.
Shen T; Li SF; Wang JL; Zhang T; Zhang S; Chen HT; Xiao QY; Ren WH; Liu C; Peng B; Ji XN; Yang Y; Lu PX; Chen TY; Yu L; Ji Y; Jiang DK
Liver Int; 2020 Nov; 40(11):2834-2847. PubMed ID: 32594568
[TBL] [Abstract][Full Text] [Related]
2. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
[TBL] [Abstract][Full Text] [Related]
3. Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis.
Villar S; Ortiz-Cuaran S; Abedi-Ardekani B; Gouas D; Nogueira da Costa A; Plymoth A; Khuhaprema T; Kalalak A; Sangrajrang S; Friesen MD; Groopman JD; Hainaut P
PLoS One; 2012; 7(6):e37707. PubMed ID: 22675488
[TBL] [Abstract][Full Text] [Related]
4. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
[TBL] [Abstract][Full Text] [Related]
5. Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma.
Woo HG; Wang XW; Budhu A; Kim YH; Kwon SM; Tang ZY; Sun Z; Harris CC; Thorgeirsson SS
Gastroenterology; 2011 Mar; 140(3):1063-70. PubMed ID: 21094160
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of aflatoxin induced p53 mutation at codon 249 (R249s) in hepatocellular carcinoma patients with and without hepatitis B surface antigen (HBsAg).
Chittmittrapap S; Chieochansin T; Chaiteerakij R; Treeprasertsuk S; Klaikaew N; Tangkijvanich P; Komolmit P; Poovorawan Y
Asian Pac J Cancer Prev; 2013; 14(12):7675-9. PubMed ID: 24460352
[TBL] [Abstract][Full Text] [Related]
7. Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases.
Nishioka Y; Chun YS; Overman MJ; Cao HST; Tzeng CD; Mason MC; Kopetz SW; Bauer TW; Vauthey JN; Newhook TE;
J Am Coll Surg; 2022 Apr; 234(4):474-483. PubMed ID: 35290266
[TBL] [Abstract][Full Text] [Related]
8. Droplet digital PCR detects high rate of TP53 R249S mutants in cell-free DNA of middle African patients with hepatocellular carcinoma.
Marchio A; Amougou Atsama M; Béré A; Komas NP; Noah Noah D; Atangana PJA; Camengo-Police SM; Njouom R; Bekondi C; Pineau P
Clin Exp Med; 2018 Aug; 18(3):421-431. PubMed ID: 29749584
[TBL] [Abstract][Full Text] [Related]
9. TP53 R249S mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China.
Szymañska K; Chen JG; Cui Y; Gong YY; Turner PC; Villar S; Wild CP; Parkin DM; Hainaut P
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1638-43. PubMed ID: 19366907
[TBL] [Abstract][Full Text] [Related]
10. Depicting the role of TP53 in hepatocellular carcinoma progression.
Villanueva A; Hoshida Y
J Hepatol; 2011 Sep; 55(3):724-725. PubMed ID: 21616106
[TBL] [Abstract][Full Text] [Related]
11. TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk.
Lam YK; Yu J; Huang H; Ding X; Wong AM; Leung HH; Chan AW; Ng KK; Xu M; Wang X; Wong N
Hepatology; 2023 Sep; 78(3):727-740. PubMed ID: 36221953
[TBL] [Abstract][Full Text] [Related]
12. Preoperative evaluation of microvascular invasion with circulating tumour DNA in operable hepatocellular carcinoma.
Wang D; Xu Y; Goldstein JB; Ye K; Hu X; Xiao L; Li L; Chang L; Guan Y; Long G; He Q; Yi X; Zhang J; Wang Z; Xia X; Zhou L
Liver Int; 2020 Aug; 40(8):1997-2007. PubMed ID: 32279416
[TBL] [Abstract][Full Text] [Related]
13. Association between TP53 R249S mutation and polymorphisms in TP53 intron 1 in hepatocellular carcinoma.
Ortiz-Cuaran S; Cox D; Villar S; Friesen MD; Durand G; Chabrier A; Khuhaprema T; Sangrajrang S; Ognjanovic S; Groopman JD; Hainaut P; Le Calvez-Kelm F
Genes Chromosomes Cancer; 2013 Oct; 52(10):912-9. PubMed ID: 23836507
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide association study of the TP53 R249S mutation in hepatocellular carcinoma with aflatoxin B1 exposure and infection with hepatitis B virus.
Han C; Yu T; Qin W; Liao X; Huang J; Liu Z; Yu L; Liu X; Chen Z; Yang C; Wang X; Mo S; Zhu G; Su H; Li J; Qin X; Gui Y; Mo Z; Li L; Peng T
J Gastrointest Oncol; 2020 Dec; 11(6):1333-1349. PubMed ID: 33457005
[TBL] [Abstract][Full Text] [Related]
15. Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein.
Gouas DA; Shi H; Hautefeuille AH; Ortiz-Cuaran SL; Legros PC; Szymanska KJ; Galy O; Egevad LA; Abedi-Ardekani B; Wiman KG; Hantz O; Caron de Fromentel C; Chemin IA; Hainaut PL
Carcinogenesis; 2010 Aug; 31(8):1475-82. PubMed ID: 20538734
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus genetic variation and TP53 R249S mutation in patients with hepatocellular carcinoma in Thailand.
Thongbai C; Sa-nguanmoo P; Kranokpiruk P; Poovorawan K; Poovorawan Y; Tangkijvanich P
Asian Pac J Cancer Prev; 2013; 14(6):3555-9. PubMed ID: 23886144
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma.
Oversoe SK; Clement MS; Pedersen MH; Weber B; Aagaard NK; Villadsen GE; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
Scand J Gastroenterol; 2020 Dec; 55(12):1433-1440. PubMed ID: 33103505
[TBL] [Abstract][Full Text] [Related]
18. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.
von Felden J; Craig AJ; Garcia-Lezana T; Labgaa I; Haber PK; D'Avola D; Asgharpour A; Dieterich D; Bonaccorso A; Torres-Martin M; Sia D; Sung MW; Tabrizian P; Schwartz M; Llovet JM; Villanueva A
Oncogene; 2021 Jan; 40(1):140-151. PubMed ID: 33097857
[TBL] [Abstract][Full Text] [Related]
19. Seasonal variation in TP53 R249S-mutated serum DNA with aflatoxin exposure and hepatitis B virus infection.
Villar S; Le Roux-Goglin E; Gouas DA; Plymoth A; Ferro G; Boniol M; Lereau M; Bah E; Hall AJ; Wild CP; Mendy M; Norder H; van der Sande M; Whittle H; Friesen MD; Groopman JD; Hainaut P
Environ Health Perspect; 2011 Nov; 119(11):1635-40. PubMed ID: 21768053
[TBL] [Abstract][Full Text] [Related]
20. The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy.
Gouas D; Shi H; Hainaut P
Cancer Lett; 2009 Dec; 286(1):29-37. PubMed ID: 19376640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
